does tirzepatide lower blood pressure and Low Risk Tirzepatide Mechanism of Weight Loss

Does B12 actually improve energy or mood while on GLP-1s

Why is creatine supportive in perimenopause and menopause

FDA approves Wegovy for CVD risk reduction in people with overweight or obesity and established cardiovascular disease owenhaskins Mar 11, 2024 2 min read The FDA has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD)

Frequently referred to as wonder drugs, GLP-1s are increasingly recognized for their potential well beyond the treatment of diabetes and obesity alone 1

They will not affect potency or dosing accuracy as long as you draw your dose carefully